The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 1, 2000, Pages 169-179

  Lee, Chung K K ^a   Aeppli, Dorothee ^a   Nierengarten, Mary E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cardiovascular disease; Complications; Hodgkin's disease; Radiotherapy; Second malignancies

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER STAGING; CAUSE OF DEATH; CHILD; CLINICAL TRIAL; FEMALE; FOLLOW UP; HEART DISEASE; HODGKIN DISEASE; HUMAN; INCIDENCE; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND CANCER; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RECURRENCE; SALVAGE THERAPY; SEX FACTORS; SURVIVAL RATE;

EID: 0034255807     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00647-7     Document Type: Article

References (36)

1. Liao Z., Ha C.S., Fuller L.M., et al. Subdiaphragmatic stage I and II Hodgkin's disease Long-term follow-up and prognostic factors . Int J Radiat Oncol Biol Phys. 41:1998;1047-1056.
2. Aviles A., Delgado S. A prospective clinical trial comparing chemotherapy, radiotherapy, and combined therapy in the treatment of early-stage Hodgkin's disease with bulky disease. Clin Lab Haem. 20:1998;95-99.
3. Hagenbeek A., Carde P., Noordijk E., et al. Prognostic factor tailored treatment of early stage Hodgkin's disease Results from a prospective randomized phase III clinical trial in 762 patients (H7 study) [Abstract] . Blood. 90:(Suppl. 1):1997;2603.
4. Radford J.A., Cowan R.A., Ryder W.D., et al. Four weeks of neoadjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical stage IA/IIA Hodgkin's disease Results of a randomized pilot study [Abstract] . Proc Am Soc Clin Oncol. 15:1996;A1322.
5. Hoppe R.T. Hodgkin's disease Complications of therapy and excess mortality . Ann Oncol. 8:(Suppl. 1):1997;S115-S118.
6. Swerdlow A.J., Barber J.A., Horwich A., Cunningham D., Milan S., Omar R.Z. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Br J Cancer. 75:1997;116-123.
7. Beaty O. III, Hudson M., Greenwald C., et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol. 13:1995;603-609.
8. Nyandoto P., Muhonen T., Joensuu H. Second cancer among long-term survivors from Hodgkin's disease. Int J Radiat Oncol Biol Phys. 42:1998;373-378.
9. Mauch P.M., Kalish L.A., Marcus K.C., et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease Long-term analysis of risk factors and outcomes . Blood. 87:1996;3625-3632.
10. Bhatia S., Robison L.L., Oberlin O., et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 334:1996;745-751.
11. Brierley J.D., Rathmell A.J., Gospodarowicz M.K. Late effects of treatment for early-stage Hodgkin's disease. Br J Cancer. 77:1998;1300-1310.
12. Salloum E., Doria R., Schubert W., et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol. 14:1996;2435-2443.
13. Doria R., Holford T., Farber L.R., et al. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol. 13:1995;2016-2022.
14. Boivin J.F., Hutchison G.B., Zauber A.G., et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst. 87:1995;732-741.
15. Glanzmann C., Kaufmann P., Jenni R., et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol. 46:1998;51-62.
16. Constine L.S., Schwartz R.G., Savage D.E., et al. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys. 39:1997;897-906.
17. Hudson M.M., Poquette C.A., Lee J., et al. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol. 16:1998;3592-3600.
18. Lee C.K.K., Aeppli D.M., Bloomfield C.D., Levitt S.H. Hodgkin's disease Reassessment of prognostic factors following modification of radiotherapy . Int J Radiat Oncol Biol Phys. 13:1987;983-991.
19. Lee E.T. Statistical methods for survival data analysis. 1982;Wadsworth Inc, Belmont, CA.
20. SEER Cancer Statistics Review 1973-1991. National Cancer Institute, Division of Cancer Prevention and Control, Surveillance Program, U.S. Department of Health and Human Services, Public Health Services, National Institutes of Health.
21. Crow L., Gardner R.S. Confidence intervals for the expectation of a Poisson variable. Biometrika. 46:1959;441-453.
22. Henry-Amar M., Somers R. Survival outcome after Hodgkin's disease A report from the International Data Base on Hodgkin's Disease . Sem Oncol. 17:1990;758-768.
23. Mauch P.M., Kalish L.A., Marcus K., et al. Long-term survival in Hodgkin's disease Relative impact of mortality, second tumors, infection, and cardiovascular disease . Cancer J. 1:1995;33-42.
24. Rodriguez M.A., Fuller L.M., Zimmerman S.O., et al. Hodgkin's disease Study of treatment intensities and incidences of second malignancies . Ann Oncol. 4:1993;125-131.
25. Hancock S.L., Hoppe R.T. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Sem Radiat Oncol. 6:1996;225-242.
26. Biti G., Cellai E., Magrini S.M., et al. Second solid tumors and leukemia after treatment for Hodgkin's disease An analysis of 1121 patients from a single institution . Int J Radiat Oncol Biol Phys. 29:1994;25-31.
27. van Leeuwen F.E., Klokman W.J., Hagenbeek A., Noyan R., van den Belt-Dusebout A.W., van Kerkhoff E.H.M., et al. Second cancer risk following Hodgkin's disease A 20-year follow-up study . J Clin Oncol. 12:1994;312-325.
28. Abrahamsen J.F., Andersen A., Hannisdal E., et al. Second malignancies after treatment of Hodgkin's disease The influence of treatment, follow-up time, and age . J Clin Oncol. 11:1993;255-261.
29. Tinger A., Wasserman T.H., Klein E.E., Miller E.A., Roberts T., Piephoff J.V., Kucik N.A. The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique. Int J Radiat Oncol Biol Phys. 37:1997;865-870.
30. Aisenberg A.C., Finkelstein D.M., Doppke K.P., et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 79:1997;1203-1210.
31. Hancock S.L., Tucker M.A., Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 270:1993;1949-1955.
32. Joensuu H. Myocardial infarction after irradiation in Hodgkin's disease A review . Recent Results Cancer Res. 130:1993;159-173.
33. Boivin J.F., Hutchinson G.B., Lubin J.H., et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer. 69:1992;1241-1247.
34. Vlachaki M.T., Ha C.S., Hagemeister F.B., Fuller L.M., Rodriguez M.A., Besa P.C., Hess M.A., Brown B., Cabanillas F., Cox J.D. Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease Patterns of failure, late toxicity, and second malignancies . Int J Radiat Oncol Biol Phys. 39:1997;609-616.
35. Cooper D.L. Treatment of early-stage Hodgkin's disease Lessons from recent studies . Principles Pract Oncol. 13:1999;1-10.
36. Salloum E, Tanoue LT, Wackers F.JTh; et al. Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation. Cancer Investig 1999;17:171-180.